- Home
- CRBP vs AIRE Comparison
CRBP vs AIRE Comparison
Compare CRBP & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- AIRE
- Stock Information
- Founded
- CRBP 2009
- AIRE 2021
- Country
- CRBP United States
- AIRE United States
- Employees
- CRBP N/A
- AIRE N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- AIRE
- Sector
- CRBP Health Care
- AIRE
- Exchange
- CRBP Nasdaq
- AIRE Nasdaq
- Market Cap
- CRBP 73.4M
- AIRE 86.1M
- IPO Year
- CRBP N/A
- AIRE N/A
- Fundamental
- Price
- CRBP $6.03
- AIRE $0.66
- Analyst Decision
- CRBP Strong Buy
- AIRE Strong Buy
- Analyst Count
- CRBP 10
- AIRE 1
- Target Price
- CRBP $60.89
- AIRE $3.00
- AVG Volume (30 Days)
- CRBP 207.2K
- AIRE 277.2K
- Earning Date
- CRBP 05-06-2025
- AIRE 05-23-2025
- Dividend Yield
- CRBP N/A
- AIRE N/A
- EPS Growth
- CRBP N/A
- AIRE N/A
- EPS
- CRBP N/A
- AIRE N/A
- Revenue
- CRBP N/A
- AIRE $948,420.00
- Revenue This Year
- CRBP N/A
- AIRE $235.72
- Revenue Next Year
- CRBP $150.00
- AIRE $135.87
- P/E Ratio
- CRBP N/A
- AIRE N/A
- Revenue Growth
- CRBP N/A
- AIRE 419.58
- 52 Week Low
- CRBP $4.64
- AIRE $0.52
- 52 Week High
- CRBP $61.90
- AIRE $4.49
- Technical
- Relative Strength Index (RSI)
- CRBP 49.07
- AIRE 31.20
- Support Level
- CRBP $5.68
- AIRE $0.60
- Resistance Level
- CRBP $6.29
- AIRE $0.85
- Average True Range (ATR)
- CRBP 0.46
- AIRE 0.09
- MACD
- CRBP 0.19
- AIRE -0.01
- Stochastic Oscillator
- CRBP 84.24
- AIRE 22.20
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About AIRE reAlpha Tech Corp.
ReAlpha Tech Corp is a real estate technology company that develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability; and has an app for investment into the properties that it purchased aimed at retail investors. The company's reportable segments are; Platform Services, which derives key revenue, and the Rental business segment.